These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 27655435)

  • 1. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
    Okkenhaug K; Graupera M; Vanhaesebroeck B
    Cancer Discov; 2016 Oct; 6(10):1090-1105. PubMed ID: 27655435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 4. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
    Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
    J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
    Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
    Fruman DA; Rommel C
    Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
    Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
    Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
    Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
    Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
    Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
    Hart S; Novotny-Diermayr V; Goh KC; Williams M; Tan YC; Ong LC; Cheong A; Ng BK; Amalini C; Madan B; Nagaraj H; Jayaraman R; Pasha KM; Ethirajulu K; Chng WJ; Mustafa N; Goh BC; Benes C; McDermott U; Garnett M; Dymock B; Wood JM
    Mol Cancer Ther; 2013 Feb; 12(2):151-61. PubMed ID: 23270925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
    Curigliano G; Shah RR
    Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G; Hassenrück F; Hallek M
    Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential PI3Kδ Signaling in CD4
    Ahmad S; Abu-Eid R; Shrimali R; Webb M; Verma V; Doroodchi A; Berrong Z; Samara R; Rodriguez PC; Mkrtichyan M; Khleif SN
    Cancer Res; 2017 Apr; 77(8):1892-1904. PubMed ID: 28108509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
    Stamatkin C; Ratermann KL; Overley CW; Black EP
    Cancer Biol Ther; 2015; 16(9):1341-52. PubMed ID: 26176612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
    Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
    Front Immunol; 2021; 12():608625. PubMed ID: 33790890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.